Veronika Vojáčková

Veronika Vojáčková

Auto-generated profile, based on publicly available information

Veronika Vojáčková

Department of Experimental Biology, Faculty of Science, Palacký University, Šlechtitelů 27, 77900 Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RJRadek Jorda
Radek Jorda
LHLibor Havlíček
Libor Havlíček
MPMiroslav Peřina
Miroslav Peřina
VVVeronika Vojáčková
Veronika Vojáčková
TPTomas Pospisil
Tomas Pospisil
VKVladimir Krystof
Vladimir Krystof

3 August 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
PBPetra Břehová
Petra Břehová
EŘEva Řezníčková
Eva Řezníčková
KŠKryštof Škach
Kryštof Škach
RJRadek Jorda
Radek Jorda
MDMilan Dejmek
Milan Dejmek
VKVladimir Krystof
Vladimir Krystof
FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3 mutations typically have higher relapse rates and worse outcomes than patients without FLT3 mutations. In this study, we investigated the suitability of various heterocycles as central cores of FLT3 inhibitors, including thieno[3,2-d]pyrimidine, pyrazolo[1,5-a]pyrimidine, imidazo[4,5-b]pyridine, pyrido[4,3-d]pyrimidine, and imidazo[1,2-b]pyridazine. Our assays revealed a series of imidazo[1,2-b]pyridazines with high potency against FLT3. Compound 34f showed nanomolar inhibitory activity against recombinant FLT3-ITD and FLT3-D835Y (IC50 values 4 and 1 nM, respectively) as well as in the FLT3-ITD-positive AML cell lines MV4-11, MOLM-13, and MOLM-13 expressing the FLT3-ITD-D835Y mutant (GI50 values of 7, 9, and 4 nM, respectively). In contrast, FLT3-independent cell lines were much less sensitive. In vitro experiments confirmed suppression of FLT3 downstream signaling pathways. Finally, the treatment of MV4-11 xenograft-bearing mice with 34f at doses of 5 and 10 mg/kg markedly blocked tumor growth without any adverse effects.

26 January 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
EREslam Roshdy
Eslam Roshdy
EŘEva Řezníčková
Eva Řezníčková
MEMostafa M. Elbadawi
Mostafa M. Elbadawi
ICIsmail Celik
Ismail Celik
SGSimone Giovannuzzi
Simone Giovannuzzi
Manabu AbeManabu Abe
Manabu Abe
Leukemia remains a challenging hematological malignancy, with limited therapeutic options. To address this unmet need, we report quinoline-sulfonamide hybrids as first-in-class dual inhibitors of platelet-derived growth factor receptor (PDGFR) and carbonic anhydrase (CA) IX/XII. Structure-activity relationship studies identified compound 9d as a potent lead, exhibiting strong inhibition of PDGFRA (IC50 = 20 nM) and CA IX/XII (KI = 93.3 and 80.0 nM, respectively), along with exceptional antiproliferative activity in FIP1L1-PDGFRA-driven EOL-1 cells (GI50 = 2 nM), comparable to clinical agents. Mechanistic analyses revealed that 9d effectively abrogates PDGFRA signaling, induces G0/G1 cell-cycle arrest, and triggers apoptosis. Molecular docking and 200 ns molecular dynamics simulations supported stable dual binding of 9d within the ATP-binding pocket of PDGFR and the catalytic cleft of CA IX. By simultaneously targeting oncogenic PDGFRA signaling and hypoxia-driven pH regulation (CA IX/XII), 9d represents a promising lead for preclinical development in PDGFR/CA IX/XII-driven leukemias.

31 May 2022 in ChemMedChem
Verified
Journal Article
Closed access
AFAndreia Fortuna
Andreia Fortuna
RPRita Gonçalves Pereira
Rita Gonçalves Pereira
Paulo J. CostaPaulo J. Costa
Paulo J. Costa
RJRadek Jorda
Radek Jorda
VVVeronika Vojáčková
Veronika Vojáčková
Nuno Manuel XavierNuno Manuel Xavier
Nuno Manuel Xavier

7 June 2023 in Journal of Molecular Structure
Verified
Journal Article
Closed access
AGAb Majeed Ganai
Ab Majeed Ganai
TPTabasum Khan Pathan
Tabasum Khan Pathan
SMSachin Balaso Mohite
Sachin Balaso Mohite
VVVeronika Vojáčková
Veronika Vojáčková
EŘEva Řezníčková
Eva Řezníčková
RKRajshekhar Karpoormath
Rajshekhar Karpoormath

5 July 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
GVGabrielė Varvuolytė
Gabrielė Varvuolytė
EŘEva Řezníčková
Eva Řezníčková
ABAurimas Bieliauskas
Aurimas Bieliauskas
NKNeringa Kleiziene
Neringa Kleiziene
VVVeronika Vojáčková
Veronika Vojáčková
AŠAlgirdas Šačkus
Algirdas Šačkus
A series of new indole‐pyrazole hybrids 8a–m were synthesized through the palladium‐catalyzed ligandless Heck coupling reaction from easily accessible unsubstituted, methoxy‐ or fluoro‐substituted 4‐ethenyl‐1H‐pyrazoles and 5‐bromo‐3H‐indoles. These compounds exerted cytotoxicity to melanoma G361 cells when irradiated with blue light (414 nm) and no cytotoxicity in the dark at concentrations up to 10 µM, prompting us to explore their photodynamic effects. The photodynamic properties of the example compound 8d were further investigated in breast cancer MCF‐7 cells. Evaluation revealed comparable anticancer activities of 8d in both breast and melanoma cancer cell lines within the submicromolar range. The treatment induced a massive generation of reactive oxygen species, leading to different types of cell death depending on the compound concentration and the irradiation intensity.